Moderna is a step closer to showing detractors that it is no moonshot stock. The biotech group on Monday said its experimental Covid-19 vaccine was 94.5 per cent effective, according to preliminary data. That makes it the second US company, after Pfizer and its German partner BioNTech, to report positive results from late-stage clinical trials.
Moderna朝着向诋毁者表明它不是成功几率极小的股票走近了一步。这家生物技术集团周一表示，根据初步数据，其实验性新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）疫苗的有效率达到94.5%。这使其成为继辉瑞(Pfizer)及其德国合作伙伴BioNTech之后、第二家报告后期临床试验积极结果的美国公司。
您已阅读17%（502字），剩余83%（2397字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。